These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

494 related items for PubMed ID: 20856241

  • 1. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
    Burke KA, Freeman SN, Imoisili MA, Coté TR.
    Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
    [Abstract] [Full Text] [Related]

  • 2. Rare diseases, orphan drugs, and orphaned patients.
    Scheindlin S.
    Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
    [No Abstract] [Full Text] [Related]

  • 3. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME.
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [Abstract] [Full Text] [Related]

  • 4. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
    Wellman-Labadie O, Zhou Y.
    Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
    [Abstract] [Full Text] [Related]

  • 5. "Creating hope" and other incentives for drug development for children.
    Connor E, Cure P.
    Sci Transl Med; 2011 Jan 19; 3(66):66cm1. PubMed ID: 21248312
    [Abstract] [Full Text] [Related]

  • 6. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC, He L, He G, He Y.
    J Public Health Policy; 2010 Dec 19; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [Abstract] [Full Text] [Related]

  • 7. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT.
    Adv Exp Med Biol; 2017 Dec 19; 1031():183-196. PubMed ID: 29214572
    [Abstract] [Full Text] [Related]

  • 8. Regulators adopt more orphan drugs.
    Reardon S.
    Nature; 2014 Apr 03; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract] [Full Text] [Related]

  • 9. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
    Thorat C, Xu K, Freeman SN, Bonnel RA, Joseph F, Phillips MI, Imoisili MA.
    Pediatrics; 2012 Mar 03; 129(3):516-21. PubMed ID: 22371464
    [Abstract] [Full Text] [Related]

  • 10. The Minor Use and Minor Species Animal Health Act: past, present, and future.
    Haley CJ.
    Food Drug Law J; 2006 Mar 03; 61(1):13-43. PubMed ID: 16838456
    [No Abstract] [Full Text] [Related]

  • 11. Adopting orphan drugs--two dozen years of treating rare diseases.
    Haffner ME.
    N Engl J Med; 2006 Feb 02; 354(5):445-7. PubMed ID: 16452556
    [No Abstract] [Full Text] [Related]

  • 12. The routes to orphan drug designation--our recent experience at the FDA.
    Lev D, Thorat C, Phillips I, Thomas M, Imoisili MA.
    Drug Discov Today; 2012 Feb 02; 17(3-4):97-9. PubMed ID: 22210120
    [No Abstract] [Full Text] [Related]

  • 13. [Orphan drugs--medications for patients with rare diseases].
    Thielke D, Thyssen JP, Hansen BJ.
    Ugeskr Laeger; 2006 Jun 05; 168(23):2236-8. PubMed ID: 16768975
    [Abstract] [Full Text] [Related]

  • 14. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
    Karas L, Lu CY, Agrawal PB, Asgari MM.
    J Am Acad Dermatol; 2019 Sep 05; 81(3):867-877. PubMed ID: 31103566
    [Abstract] [Full Text] [Related]

  • 15. The Orphan Drug Act Revisited.
    Thomas S, Caplan A.
    JAMA; 2019 Mar 05; 321(9):833-834. PubMed ID: 30768155
    [No Abstract] [Full Text] [Related]

  • 16. Orphan drugs and orphan tests in the USA.
    Thoene JG.
    Community Genet; 2004 Mar 05; 7(4):169-72. PubMed ID: 15692190
    [No Abstract] [Full Text] [Related]

  • 17. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR, Xu K, Milto J, Coté TR.
    Discov Med; 2011 Apr 05; 11(59):367-75. PubMed ID: 21524390
    [Abstract] [Full Text] [Related]

  • 18. Rare opportunities appear on the horizon to treat rare diseases.
    Torres C.
    Nat Med; 2010 Mar 05; 16(3):241. PubMed ID: 20208483
    [No Abstract] [Full Text] [Related]

  • 19. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M, Kubácková K, Palágyi M, Smíd M.
    Cas Lek Cesk; 2006 Mar 05; 145(4):296-300. PubMed ID: 16639930
    [Abstract] [Full Text] [Related]

  • 20. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE, Leufkens HG, Rodgers RP, Xu K, Voordouw BC, Braun MM.
    Drug Discov Today; 2011 Jan 05; 16(1-2):73-80. PubMed ID: 21094692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.